Durect — Investor Presentation (February 2023)
27 slides from Durect's investor presentation, Feb 3, 2023
Slide 1: Unlocking Epigenetic Therapeutics to Revolutionize Medicine
Unlocking Epigenetic Therapeutics to Revolutionize Medicine February 2023 Exhibit 99.1
Slide 2: Disclaimer
Disclaimer This presentation and various remarks we make during this presentation contain forward-looking statements of DURECT Corporation ("DURECT," the "Company," "we," "our" or "us") and its collaborative partners within the meaning of applicable securities laws and regulations, including stateme
Slide 3: Company Highlights
Company Highlights Harnessing the power of epigenetic regulation Larsucosterol: Potential first-in-class treatment for AH Potential pivotal trial ongoing; data expected in 2H 2023 Compelling Phase 2a data in AH Significant unmet need in AH – no approved therapy POSIMIR® launched in September 2022 AH
Slide 4: Late Stage Pipeline Addressing Potentially Large Market Opportunities
Late Stage Pipeline Addressing Potentially Large Market Opportunities Program Indication Phase 1 Phase 2 Phase 3 Approved Status Epigenetic Regulator Program Larsucosterol (DUR-928) Alcohol-Associated Hepatitis (AH) Enrolling Phase 2b AHFIRM Trial Topline data expected 2H 2023 Non-Alcoholic Steatohe
Slide 5: Larsucosterol Overview
Larsucosterol Overview Lead Compound in DURECT’s Epigenetic Regulator Program Modulator of DNA methylation Clinical safety Role in cellular functions Broad therapeutic potential New class of therapeutics Endogenous sulfated oxysterol Highly conserved across all 7 species studied to date Stabilizes m
Slide 6: Larsucosterol Potential in Alcohol-associated Hepatitis
Larsucosterol Potential in Alcohol-associated Hepatitis
Slide 7: What is Alcohol-associated Hepatitis?
Reference: 1 Hughes E, Hopkins LJ, Parker R (2018). PLoS ONE 13(2): e0192393 What is Alcohol-associated Hepatitis? A subset of alcohol-associated liver disease (ALD) May occur suddenly after binge drinking episode Characterized by jaundice and severe inflammation – indicative of SIRS (Systemic Infla
Slide 8: AH Lacks Effective Treatment Options with No Approved Therapy
AH Lacks Effective Treatment Options with No Approved Therapy Corticosteroids used off label despite no long-term survival benefit and increased risk of infection1 Fewer than 50% of AH patients are eligible for corticosteroids2 Stopping alcohol consumption is not sufficient in many patients3 Liver t
Slide 9: AH Imposes High Economic Burden on Healthcare System
AH Imposes High Economic Burden on Healthcare System ~158,000 U.S. hospitalizations per year1 AH hospitalizations increased by approximately 4.8% per year between 2015 and 20182 86% of hospitalized AH patients are insured2 Each hospitalization episode with AH diagnosis for patients who: Average leng
Slide 10: Larsucosterol Phase 2a Trial in AH
Larsucosterol Phase 2a Trial in AH
Slide 11: Larsucosterol: Summary of Phase 2a Trial in AH
Larsucosterol: Summary of Phase 2a Trial in AH Patients received up to two doses of larsucosterol on Day 1 and Day 4 (if still hospitalized) Multiple dose levels studied: 30mg, 90mg and 150mg Showed improvement in key biomarkers and prognostic indicators Reduction in bilirubin and Model for End-stag
Slide 12: Phase 2a: Majority of Patients Discharged After One Dose
Phase 2a: Majority of Patients Discharged After One Dose Potential Pharmacoeconomic Benefit as Measured by Time to Discharge Number (%) of patients who were discharged in ≤ 4 days after receiving a single dose of larsucosterol All patients (n=19) 14/19 (74%) Severe patients (MELD 21-30) (n=12) 8/12
Slide 13: Phase 2a: Reduction in Bilirubin & MELD Across Patient Categories
Phase 2a: Reduction in Bilirubin & MELD Across Patient Categories More Pronounced Effect in Patients with Higher Bilirubin One of 19 patients did not return for the follow-up visits on Day 7 and Day 28; all data were analyzed based on those who completed visits.
Slide 14: Phase 2a: Lille Score Provides Strong Signal for Survival
Phase 2a: Lille Score Provides Strong Signal for Survival Composite score that determines response to treatment and risk of death Larsucosterol treatment resulted in 89% (16/18) response rate by Lille Score (< 0.45) 85% Survival 25% Survival 1Louvet, A et al. Hepatology 2007; 45:1348-1354. 2n=18 ; o
Slide 15: Phase 2a: Lille Score Comparison to UL Historical Control
Phase 2a: Lille Score Comparison to UL Historical Control Larsucosterol treatment had 76% lower median Lille score vs. matched historical control 0.45 0.45 Larsucosterol2 larsucosterol larsucosterol Larsucosterol larsucosterol 1Anonymized data provided by Dr. Craig McClain from the University of Lou
Slide 16: Phase 2a: Larsucosterol Was Well Tolerated Across All Doses
Phase 2a: Larsucosterol Was Well Tolerated Across All Doses No Serious Adverse Events attributed to trial drug No discontinuations, early withdrawal or termination of trial drug or trial participation due to AEs Adverse events possibly related to larsucosterol: 1 occurrence each of moderate generali
Slide 17: Larsucosterol AHFIRM Trial
Larsucosterol AHFIRM Trial Phase 2b Trial in Alcohol-associated Hepatitis to Evaluate SaFety and EffIcacy of LaRsucosterol TreatMent
Slide 18: Larsucosterol: Potential to be First Approved Therapy for AH
Larsucosterol: Potential to be First Approved Therapy for AH AHFIRM: Phase 2b double-blind, placebo-controlled efficacy trial in 300 severe AH patients Expect to complete enrollment in Q2 2023 with topline data in 2H 2023 Primary endpoint is reduction in mortality or liver transplant at 90 days Pote
Slide 19: AHFIRM Trial Design Leverages Lessons from Phase 2a Trial
AHFIRM Trial Design Leverages Lessons from Phase 2a Trial Aim: Demonstrate Safety and Efficacy in Severe AH 4-Day Treatment Study Design2 Screening Period 30 mg larsucosterol 90 mg larsucosterol Placebo Severe AH patients with MDF1 score ≥ 32 and MELD score 21-30 300 subjects in three groups in a 1:
Slide 20: Lille Score Comparison vs. Historical Control in Severe AH
Lille Score Comparison vs. Historical Control in Severe AH Larsucosterol AHFIRM doses (30mg & 90mg) produced lower Lille scores in Phase 2a vs. historical control (corticosteroids) Baseline AH Severity Steroid (n=13) Larsucosterol (n=8) Mean Baseline MELD (Severe AH ≥ 21) 24.5 24.5 Mean Baseline MDF
Slide 21: POSIMIR (bupivacaine solution)
POSIMIR® (bupivacaine solution)
Slide 22: POSIMIR (bupivacaine solution) for infiltration use
POSIMIR® (bupivacaine solution) for infiltration use FDA approved in arthroscopic subacromial decompression Exclusive U.S. license to Innocoll Pharmaceuticals – launched in September 2022 Earned $10 million in milestones during Q3 2022 based on recent patent issuance and first commercial sale Additi
Slide 23: Financial Overview and Summary
Financial Overview and Summary
Slide 24: Financial Overview
Financial Overview Nasdaq DRRX Market Cap $158.6 MM1 Shares O/S 22.8 MM2 Cash & Cash Equivalents $43.6 MM2 Debt $21.2 MM2 Federal NOLs $352 MM3 1 As of January 11, 2023 2 As of December 31, 2022 3 As of December 31, 2021 Cupertino, CA headquarters
Slide 25: Larsucosterol – Positioned for Success in AH
Larsucosterol – Positioned for Success in AH Global, randomized, double-blind, placebo-controlled efficacy trial 300 patient, 3 arm trial Clearly-defined patient population Straightforward endpoint Well positioned to show potential clinical benefit Fast Track Designation Robust Phase 2b Trial w/ Reg
Slide 26: Appendix
eke 4s; By A a) " Appendix COC $a “4 Fo) durect
Slide 27: Inhibition of DNMT-1, 3a & 3b Aligns with AH
Inhibition of DNMT-1, 3a & 3b Aligns with AH References: Wang Y et al. 2021, Journal of Lipid Research, 62:1-14 Note: in this paper, larsucosterol is referred to as 25HC3S Argemi et al. 2019. Nature Communications, 10: 3126 Liver samples from patients with severe AH have increased expression of DNMT